123). It is notable that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This means that GLS2 could confer resistance to GLS1-precise inhibitors, such as the allosteric inhibitor BPTES or CB-839, which resistance may be hypothetically avoided by https://alexisatlev.bloggosite.com/35594366/sepantronium-bromide-options